Skip to main content
Equibles
GENB logo

GENB · Generate Biomedicines, Inc. · Metrics

Track GENB — free

Use GENB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GENB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.88 +0.36 (+2.29%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”
View the 10-Q filed Aug 6, 2026
Market Cap
$2.03B
Shares
128.35M

GENB metrics

34 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.52
Market cap
$2.03B

Price action

20 metrics
Price change (1W)
+0.7%
Price change (30D)
+8.0%
Price change (3M)
+20.5%
Price change (6M)
+30.2%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
88.9%
Annualized volatility (3M)
79.2%
Beta
1.3
RSI (14D)
50.9
Price vs SMA 50
+4.4%
Price vs SMA 200
—
Avg volume (3M)
1.00M
Relative volume
1.3
Average dollar volume
$15.84M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
128.35M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
4.5
reciprocal yield 22.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-18.60

Growth

11 metrics
Revenue growth YoY
-37.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+288.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
8.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$457.42M
Latest balance sheet
Cash & equivalents
$135.36M
Total assets
$561.69M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
86
13F filer change QoQ
+28
Institutional ownership
77.9%

Short interest

3 metrics
Short interest
5.7%
Latest settlement · 15.1 days to cover
Days to cover
15.1d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$16,002
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 2100782 CUSIP 370920100 13F (30d) 61 filings 61 filers Visit website